Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
Top Cited Papers
- 1 April 2008
- journal article
- phase i-and-clinical-pharmacology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (10), 1588-1595
- https://doi.org/10.1200/jco.2007.14.0988
Abstract
Purpose To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001). Methods We performed a dose-escalation study in advanced cancer patients ...Keywords
This publication has 28 references indexed in Scilit:
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- mTOR and cancer therapyOncogene, 2006
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimusEuropean Journal Of Cancer, 2006
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktCancer Research, 2006
- Sirolimus‐associated interstitial pneumonitis in solid organ transplant recipientsClinical Transplantation, 2005
- The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 TranslationCell, 2005
- Phase I's, Photons, and Philosophies: New Tactics for Exploratory Clinical Trials of Concurrent ChemoradiationJournal of Clinical Oncology, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000